Developing 21st Century Medicines
RARE PEDIATRIC DISEASES
Advancing precision therapeutics for children with serious and underserved diseases
Children living with rare diseases and their families often face delayed diagnoses, limited treatment options and an uncertain future. Many of these conditions are caused by specific genetic changes, yet the development of safe and effective therapies remains challenging—particularly when the affected tissues are difficult to reach.
While significant progress has been made in genetic and clinical diagnosis, therapeutic options remain very limited. Most conditions still lack disease-modifying treatments, leaving care largely supportive and focused on symptom management. This gap underscores the urgent need for innovative approaches that can translate biological insight into meaningful clinical outcomes for affected children.
At SMDG, we are applying our scientific expertise and proprietary NanoLigand™ platforms, including NanoLigand Carriers™ and NanoLigand Blocks™. These self-assembling, non-viral peptide nanosystems are being developed to support targeted and precision medicines for serious rare pediatric diseases with significant unmet medical need.
Overcoming the Barriers to Pediatric Therapeutic Development
Our Approach to Rare Pediatric Medicine
SMDG brings together disease biology, nucleic acid therapeutics and proprietary peptide-based NanoLigand™ platforms to design targeted and precision medicines for rare pediatric diseases.
Our platforms are being developed to enable systemic administration and the targeted delivery of therapeutic agents, including RNA-based medicines, to affected cells and tissues that can be difficult to reach.
Guided by our Safe-by-Design and Simple-by-Design principles, we consider biological interactions, immune safety, repeat administration, scalability and the potential for broader access from the earliest stages of therapeutic development.
